Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omniscan in Renal Artery MRA
NCT00209391Phase 3Completed
- Sponsor
- GE HealthCare
- Start
- Sep 2003
- Primary completion
- Aug 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of gadodiamide in renal artery stenosis (RAS), sponsored by GE HealthCare. Primary endpoint: Subject level efficacy of CE-MRA in detecting stenosis (50% occlusion) of major renal arteries at 72 hours. Started Sep 2003; status: completed.
02
Drugs
gadodiamide
03
Conditions
renal artery stenosis (RAS)
Beyond the preview
Go deeper on NCT00209391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00209391.